Split donor tissue can be stored for one week

Article

Split donor tissues can be stored for up to one week before DALK and DMEK surgery, according to a paper published in the journal Ophthalmology.

Split donor tissues can be stored for up to one week before DALK and DMEK surgery, according to a paper published in the journal Ophthalmology.

Dr L. M. Heindl et al., Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany, completed a retrospective analysis of a non-randomized consecutive interventonal case series. The study included a total of 220 eyes-110 eyes with anterior stromal disease suitable for DALK and 110 eyes with endothelial disease qualifying for DMEK.

The main outcome measures were best-corrected visual acuity (BSCVA), endothelial cell density and complications rate within 12 months of follow-up. Spearman correlation coefficient and a Mann-Whitney U test was used to analyse the correlation between split donor storage times, total storages times and one-year functional morphologic outcomes.

One year after DALK the mean BSCVA was 20/30, endothelial cell loss was 8% and the complication rate was 18%. The complications included Descemet’s folds, epitheliopathy and loose sutures.

One year after DMEK mean BSCVA was 20/25, endothelial cell loss was 41% and the complication rate was 62%. The complication occurring after DMEK was partial graft detachment.

It is possible for anterior and posterior donor tissue to be stored for up to one week in organ culture before use in surgical procedures. This means the feasibility of split cornea transplantation is simplified because donor shortage and cost will decrease.

To read the paper please visit this link.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.